Document is current
Any future updates will be listed below
-
Authors
Van Damme, Ellen
Abeywickrema, Pravien
Yin, Yanting
Xie, Jiexiong
Jacobs, Sofie https://orcid.org/0000-0001-8657-6841
Mann, Mandeep Kaur https://orcid.org/0000-0002-8252-6107
Doijen, Jordi https://orcid.org/0000-0002-1707-0174
Miller, Robyn
Piassek, Madison
Marsili, Simone
Subramanian, Murali
Gottlieb, Leah
Abdelnabi, Rana https://orcid.org/0000-0001-9771-7312
Van Gool, Michiel https://orcid.org/0000-0001-5424-1377
Van den Broeck, Nick https://orcid.org/0000-0001-5900-4813
De Pauw, Ines
Diels, Annick
Vermeulen, Peter
Temmerman, Koen
Scobey, Trevor
Mattocks, Melissa
Schäfer, Alexandra https://orcid.org/0000-0002-4760-4923
Jochmans, Dirk https://orcid.org/0000-0002-9265-6028
De Jonghe, Steven https://orcid.org/0000-0002-3872-6558
Leyssen, Pieter https://orcid.org/0000-0002-7537-1688
Chiu, Winston https://orcid.org/0000-0001-5236-623X
Diosa Toro, Mayra
Zwaagstra, Marleen
Leijs, Anouk A.
De Gruyter, Heidi L. M.
Buyck, Christophe
Van Den Heede, Klaas
Jacobs, Frank https://orcid.org/0000-0002-5977-3943
Van den Eynde, Christel
Thijs, Laura
Raeymaekers, Valerie
Miller, Seth
Del Rosario, Amanda https://orcid.org/0000-0001-6107-7149
Neyts, Johan https://orcid.org/0000-0002-0033-7514
Peeters, Danielle
Baric, Ralph S. https://orcid.org/0000-0001-6827-8701
van Kuppeveld, Frank J. M. https://orcid.org/0000-0001-5800-749X
Snijder, Eric J. https://orcid.org/0000-0003-3297-2309
van Hemert, Martijn J.
Monshouwer, Mario
Sharma, Sujata https://orcid.org/0000-0002-7588-2939
Draghia-Akli, Ruxandra https://orcid.org/0000-0001-6372-4039
Koul, Anil https://orcid.org/0009-0009-5542-4568
Van Loock, Marnix https://orcid.org/0000-0003-4151-4588
- License Information
-
More Information
Article History
Received: 21 February 2024
Accepted: 15 January 2025
First Online: 26 March 2025
Competing interests
: M.V.L., E.V.D., M.V.G. and C.B. are named as inventors on a pending patent application claiming inhibitors of coronavirus (WO 2024/008909), which was filed by the Applicant Janssen Pharmaceutica. M.V.L., E.V.D., J.X., S.J., L.G., J.D., M.V.G., R.D.-A., A.D., S. Marsili, S. Miller, C.V.d.E., A.D.R., P.V., K.T., D.P. and C.B. were/are employees of Janssen Pharmaceutica and may possess stocks of Johnson & Johnson. S. Miller is an employee of Spark Therapeutics and may possess stocks of Roche. N.V.d.B., L.T., V.R. and I.D.P. are employees of Charles River Laboratories, a contract research organization and may possess stocks of Johnson & Johnson. M.S. is an employee of Gilead Sciences and may possess stocks of Gilead Sciences. A.A.L., H.L.M.d.G., E.J.S. and M.J.v.H. received funding from Janssen Pharmaceutica to perform contract research. M.D.T., M.Z. and F.J.M.v.K. received funding from Janssen Pharmaceutica to perform contract research. The other authors declare no competing interests.
